When compared with NASH Vehicle, a lowering of Galectin-3, an inflammatory marker, was observed in seladelpar, liraglutide, and seladelpar combinations (Fig. 2, A–C). The gene discussed is LGALS3; the disease is metabolic dysfunction-associated steatohepatitis.